With the advent of biologic and small molecule therapies, there has been a substantial change in the treatment of inflammatory bowel disease. These advances have had a great impact in preventing disease progression, intestinal damage and, therefore, have contributed to a better quality of life. Discordance between symptom control and mucosal healing has been demonstrated. This has led to the search for new disease control targets. The treat to target strategy, based on expert recommendations and now a randomized controlled trial, has determined that clinical and endoscopic remission should be the goal of therapy. Biomarkers (fecal calprotectin) can be a surrogate target. Although histological healing has shown benefits, there is inadequate evidence and inadequate therapy for that to be a fixed goal at this time. This review will focus on therapeutic goals, according to the evidence currently available, and evaluate strategies to achieve them.
|Título traducido de la contribución||Treat-to-target approach in the management of inflammatory Bowel disease|
|Número de páginas||8|
|Publicación||Gastroenterologia y Hepatologia|
|Estado||Publicada - abr. 2021|
|Publicado de forma externa||Sí|
Nota bibliográficaPublisher Copyright:
© 2020 Elsevier España, S.L.U.
- Crohn's disease
- Ulcerative colitis